Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
Item 1.02 Termination of a Material Definitive Agreement.
On November 2, 2012, Debiopharm S.A. provided notice to Marina Biotech, Inc. (“Marina”) that the Research and License Agreement, dated February 3, 2011, between Marina and Debiopharm, would be terminated effective December 5, 2012, due to Debiopharm’s own operational reasons. Marina had previously granted to Debiopharm an exclusive license to develop and commercialize Marina’s pre-clinical program in bladder cancer, for all uses in humans and animals for the prevention and treatment of superficial (non-muscle invasive) bladder cancer, in consideration of certain milestone and royalty payments. Following the termination of the license agreement, Marina’s bladder cancer program will be returned to us without any obligations beyond those minor activities associated with the termination period and will be reincorporated into Marina’s internal preclinical pipeline with the intention of advancing the program once either appropriate funding or a new partner is obtained.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.